Moreover, COX regression analysis for different factors affecting poor outcomes revealed that FCRL 1 overexpression is significantly associated with poor outcomes (Hazard ratio = 1.966, p = 0.037), revealing that FCRL 1 and/or BAFF therapeutic targeting may overcome such worse outcomes in DLBCL patients. Here, TNFSF13B is linked to diffuse large B-cell lymphoma.